Program
sonrotoclax
Also written as “Sonrotoclax”, “BGB-11417” and “Sonrotoclax Tablet”.
Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Mantle-Cell · Multiple Myeloma · Waldenstrom Macroglobulinemia · Leukemia, Myeloid, Acute, led by BeOne Medicines.
Drug pageSonrotoclax: every studyAll 35 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BeOne Medicines | 1613 open or running | phase 3since Oct 3, 2023 | Feb 18, 2020 | Nov 2026phase 2 · NCT04973605 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 1 study since Feb 18, 2020.
- Feb 23, 2021Phase 2 study in Leukemia, Myeloid, AcuteNCT04771130 · 260 planned · United States, Australia, China and more
- May 7, 2021Phase 1 study in Mature B-cell MalignanciesNCT04883957 · 64 enrolled · China
- Jul 7, 2021Phase 2 study in Multiple MyelomaNCT04973605 · 246 planned · United States, Australia, Brazil and more
- Jul 21, 20222 phase 2 studiesNCT05471843, NCT05479994
- Jan 19, 2023Named sonrotoclaxINNProposed as its International Nonproprietary Name in WHO's List 128 · before, BGB-11417
- Apr 25, 2023Phase 1 study in Healthy VolunteersNCT05844111 · 6 enrolled · United States
- Jul 11, 2023Phase 2 study in Waldenstrom MacroglobulinemiaNCT05952037 · 114 enrolled · United States, Australia, Canada and more
- Oct 3, 2023Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT06073821 · 652 enrolled · United States, Australia, Austria and more
- Oct 9, 2024Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT06637501 · 94 enrolled · United States, Brazil, China and more
- Nov 18, 2024Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT06697184 · 258 planned · United States, Australia, Brazil and more
- Dec 16, 2024Phase 3 study in Lymphoma, Mantle-CellNCT06742996 · 300 planned · United States, Argentina, Australia and more
- Apr 17, 2025Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT06943872 · 630 planned · United States, Argentina, Australia and more
- Dec 2, 2025Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT07277231 · 500 planned · United States, Australia, Brazil and more
- May 22, 2026Phase 1 study in Healthy VolunteersNCT07628881 · 12 enrolled · Australia
- Sep 29, 2026Phase 1 study in Hepatic ImpairmentNCT07855991 · 12 planned
Ahead
- Nov 2026Primary completion: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT06637501
- Nov 2026Primary completion: phase 2 study in Multiple MyelomaNCT04973605
- Feb 8, 2027Primary completion: phase 1 study in Hepatic ImpairmentNCT07855991
- May 31, 2027Primary completion: phase 1 study in Mature B-Cell MalignanciesNCT04277637
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07855991Hepatic Impairment | 1 | Not yet recruiting | Feb 8, 2027 | 12 |
| NCT07628881Healthy Volunteers · Australia | 1 | Completed | Sep 26, 2026 | 12 |
| NCT07277231Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Brazil and more | 3 | Recruiting | Feb 2031 | 500 |
| NCT06943872Leukemia, Lymphocytic, Chronic, B-Cell · United States, Argentina, Australia and more | 3 | Recruiting | Sep 30, 2029 | 630 |
| NCT06742996Lymphoma, Mantle-Cell · United States, Argentina, Australia and more | 3 | Recruiting | Aug 31, 2028 | 300 |
| NCT06697184Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Brazil and more | 2 | Recruiting | Nov 30, 2029 | 258 |
| NCT06637501Leukemia, Lymphocytic, Chronic, B-Cell · United States, Brazil, China and more | 2 | Active, not recruiting | Nov 2026 | 94 |
| NCT06073821Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more | 3 | Active, not recruiting | Feb 2032 | 652 |
| NCT05952037Waldenstrom Macroglobulinemia · United States, Australia, Canada and more | 2 | Active, not recruiting | Sep 22, 2026 | 114 |
| NCT05844111Healthy Volunteers · United States | 1 | Completed | Jun 18, 2023 | 6 |
| NCT05479994Leukemia · China | 2 | Active, not recruiting | Jan 24, 2025 | 100 |
| NCT05471843Lymphoma, Mantle-Cell · United States, Argentina, Belgium and more | 2 | Active, not recruiting | Jul 18, 2025 | 125 |
| NCT04973605Multiple Myeloma · United States, Australia, Brazil and more | 2 | Recruiting | Nov 2026 | 246 |
| NCT04883957Mature B-cell Malignancies · China | 1 | Completed | Sep 1, 2026 | 64 |
| NCT04771130Leukemia, Myeloid, Acute · United States, Australia, China and more | 2 | Recruiting | Aug 31, 2028 | 260 |
| NCT04277637Mature B-Cell Malignancies · United States, Australia, Germany and more | 1 | Active, not recruiting | May 31, 2027 | 437 |
How it is read
Names in the registry
- “Sonrotoclax”, 11 entries
- “BGB-11417”, 5 entries
- “Sonrotoclax Tablet”, 1 entry
- “[14C]-BGB-11417”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Lymphocytic, Chronic, B-Cell, 6 studies
- Lymphoma, Mantle-Cell, 2 studies
- Multiple Myeloma, 1 study
- Waldenstrom Macroglobulinemia, 1 study
- Leukemia, Myeloid, Acute, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.